OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
| RYCFX Fund | USD 53.83 0.12 0.22% |
Slightly above 62% of Biotechnology Fund's investor base is looking to short. The analysis of overall sentiment of trading Biotechnology Fund Class mutual fund suggests that many investors are alarmed at this time. Biotechnology Fund's investing sentiment can be driven by a variety of factors including economic data, Biotechnology Fund's earnings reports, geopolitical events, and overall market trends.
BIOTECHNOLOGY |
Outlook Therapeutics stock tanks 65 percent as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
Read at finance.yahoo.com
 |
Biotechnology Fund Fundamental Analysis
We analyze Biotechnology Fund's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Biotechnology Fund using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Biotechnology Fund based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Biotechnology Fund is currently under evaluation in probability of bankruptcy among similar funds. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Biotechnology Fund Class Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Biotechnology Fund mutual fund to make a market-neutral strategy. Peer analysis of Biotechnology Fund could also be used in its relative valuation, which is a method of valuing Biotechnology Fund by comparing valuation metrics with similar companies.
Peers
Biotechnology Fund Related Equities
| LGLSX | L Abbett | 0.95 | ||||
| EIPIX | Eip Growth | 0.90 | ||||
| TRBCX | T Rowe | 0.85 | ||||
| NMFAX | Nationwide Growth | 0.64 | ||||
| APDSX | Artisan Small | 0.45 | ||||
| CHASX | Chase Growth | 0.40 | ||||
| KSCYX | Kinetics Small | 1.52 |
Other Information on Investing in BIOTECHNOLOGY Mutual Fund
Biotechnology Fund financial ratios help investors to determine whether BIOTECHNOLOGY Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in BIOTECHNOLOGY with respect to the benefits of owning Biotechnology Fund security.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |